Irritable bowel syndrome gains new treatment
Amitiza has gained a new indication-to treat irritable bowel syndrome with constipation in women.
Amitiza (lubiprostone), formerly approved to treat chronic idiopathic constipation, has gained clearance for a new indication. The drug can now be used to treat irritable bowel syndrome with constipation (IBS-C) in adult women. According to Sucampo Pharmaceuticals and Takeda Pharmaceuticals America, the product is the only approved treatment for IBS-C in this country.
Recent Videos
Related Content
Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear
Brian Nowosielski;Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP;Ashley Gallagher
January 13th 2025Article
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.
